For example, obesity-related HFpEF with or without hyperlipidemia or diabetes may benefit from combined sodium–glucose cotransporter-2 inhibitors (SGLT2i), mineralocorticoid receptor antagonists (MRA), and angiotensin receptors/neprilysin inhibitor (ARNi) due to an inner deficiency of effective natriuretic peptide from excessive visceral adiposity [43]. Here, NR3C2 is linked to obesity disorder.